Codexis Inc. (CDXS)
NASDAQ: CDXSIndustrialsMajor ChemicalsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CDXS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $110.69M
- EPS (TTM)
- -$0.18
- Dividend yield
- None
- 52-week range
- 0.90 – 2.98
- Day range
- 0.98 – 1.06
- Volume / Avg
- 2.07M / 918.15K
- Beta
- —
- Shares outstanding
- 109.60M
52-week range
CDXS stock today
Codexis (CDXS) closed at $1.01 on Nov 20, down 3.81% (-$0.04), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 2.07M shares, a sign of unusually heavy trading. At this level, CDXS sits near the bottom of its 52-week range of $0.90 to $2.98: 66.1% below the high, set on May 11, 2026 and 12.2% above the low.
CDXS is down 38.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.4%. Codexis has posted a net loss over the last twelve months (EPS of -$0.18), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Codexis
Company profileCodexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
- Sector
- Industrials
- Industry
- Major Chemicals
- CEO
- Dr. Alison Moore Ph.D.
- Headquarters
- Redwood City, CA
- Employees
- 146
- IPO year
- 2010
- Website
- codexis.com
Financial highlights
Full financialsIn fiscal 2025, Codexis generated $70.4 million in revenue, up 18.6% from fiscal 2024. Codexis reported a net loss of $44.0 million, compared with a loss of $65.3 million a year earlier. Gross margin was 86.7% (up from 72.6%) and operating margin -59.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $70.39M | $59.34M | $70.14M | $138.59M | $104.75M |
| Growth | +18.61% | -15.39% | -49.39% | +32.30% | +51.69% |
| Net income | $-43.97M | $-65.28M | $-76.24M | $-33.59M | $-21.28M |
| EPS (diluted) | $-0.50 | $-0.89 | $-1.12 | $-0.51 | $-0.33 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$6.14+507.92%
- Strong buy 1
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.22 vs $-0.09
- Surprise
- -144.44%
CDXS news
All CDXS news- Codexis to Participate in Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- Codexis (CDXS) Q3 2026 Earnings Call TranscriptNasdaq
- Codexis Enters into $60 Million Term Loan Facility with Trinity CapitalGlobeNewswireCDXS, TRIN
- Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing CapabilitiesGlobeNewswire
- Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue EstimatesNasdaqRVMD, CDXS
- Codexis to Report Third Quarter 2026 Financial Results on November 12GlobeNewswire
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report DataNasdaqABBV, AZN, CBLL, CDXS
Codexis peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACNTAscent Industries Co. | 12.42 | -0.88% | $112.05M | vs CDXS |
| LODEComstock Inc. | 1.32 | -2.94% | $100.39M | vs CDXS |
| ARQArq Inc. | 2.82 | -3.42% | $124.61M | vs CDXS |
| LTBRLightbridge Corporation | 3.24 | -9.13% | $125.40M | vs CDXS |
| FFFutureFuel Corp. | 2.93 | -2.33% | $128.52M | vs CDXS |
| FSIFlexible Solutions International Inc. | 5.86 | -1.18% | $74.86M | vs CDXS |
| VGASVerde Clean Fuels Inc. Class A | 0.935 | -1.58% | $62.69M | vs CDXS |
| AMTXAemetis Inc. (DE) | 0.8092 | -14.52% | $59.15M | vs CDXS |
Indexes, lists and sector
Codexis stock FAQ
What is Codexis's stock price today?
CDXS last traded at $1.01 as of Nov 20, 4:00 PM EST, down 3.81% on the day. Prices are delayed at least 15 minutes.
Who is Codexis's CEO?
Dr. Alison Moore Ph.D. is the chief executive officer of Codexis Inc., which has about 146 employees.
What is the CDXS 52-week high?
The 52-week high for CDXS is $2.98 and the 52-week low is $0.90. The stock is currently 66.1% below its high.